Asset Details
Do you wish to reserve the book?
Identification of EGFR kinase domain mutations among lung cancer patients in China： implication for targeted cancer therapy
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Identification of EGFR kinase domain mutations among lung cancer patients in China： implication for targeted cancer therapy
Do you wish to request the book?
Identification of EGFR kinase domain mutations among lung cancer patients in China： implication for targeted cancer therapy
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Identification of EGFR kinase domain mutations among lung cancer patients in China： implication for targeted cancer therapy
2005
Overview
Lung cancer is one of the leading causes of death with one of the lowest survival rates. However, a subset of lung cancer patients who are of Asian origin and carry somatic mutations in epidermal growth factor receptor or EGFR have responded remarkable well to two tyrosine kinase inhibitors, gefitinib and erlotinib. While EGFR mutation profiles havebeen reported from Japan, South Korea, and Taiwan, there is no such report from mainland of China where the largest pool of patients reside. In this report, we identified ten somatic mutations from a total of 41 lung cancer patients in China. Among them, seven mutations were found in 17 adenocarcinomas. In contrast to previous reports, eight of these mutations are deletions in exon 19 and two of these deletions are homozygous. These results suggest that a large portion of Chinese adenocarcinoma patients could benefit from gefitinib or erlotinib. This unique mutation profile provides a rationale to develop the next generation of EGFR inhibitors more suitable for the Chinese population.
Publisher
Nature Publishing Group UK,Nature Publishing Group,Guangzhou Institute of Biomedicine and Health (GIBH), Chinese Academy of Sciences, Guangzhou 510663 China%The State-key Laboratory for Oncogenes and Related Genes, Shanghai Cancer Institute, Shanghai Jiatong University,LN2200/25, Xietu Road, Shanghai 200032, China
Subject
